From: Radiotherapy plus temozolomide in elderly patients with glioblastoma: a “real-life” report
Median survival (months) | 12 months survival (%) | Univariate analysis | Multivariate analysis | |||
---|---|---|---|---|---|---|
HR [95%CI] | p | HR [95%CI] | p | |||
Age | ||||||
< 75.5 years | 5.6 | 18.6 | ||||
≥ 75.5 years | 5.1 | 17.8 | 1.03 [0.69–1.53] | 0.88 | 0.76 [0.49–1.20] | 0.25 # $ |
KPS | ||||||
< 70 | 3.2 | 7.5 | ||||
≥ 70 | 7.8 | 25 | 0.52 [0.34–0.77] | < 0.01 | 0.70 [0.45–1.09] | 0.11 # |
Gender | ||||||
Female | 4.5 | 15.7 | ||||
Male | 6.1 | 20.7 | 0.70 [0.47–1.05] | 0.08 | 0.71 [0.47–1.08] | 0.10 # $ |
MGMT status | ||||||
Methylated | 5.9 | 12.1 | ||||
Unmethylated | 4.8 | 17.5 | 1.14 [0.72–1.82] | 0.57 | ||
Type of surgery | ||||||
Biopsy | 4.8 | 50 | ||||
Resection | 13.5 | 13 | 0.43 [0.24–0.77] | < 0.05 | 0.47 [0.26–0.86] | < 0.05 # |
RPA class | ||||||
I-II | 13.5 | 50 | ||||
III | 5.5 | 15.4 | 1.95 [1.07–3.57] | < 0.05 * | 2.15 [1.17–3.95] | < 0.05 $ * |
IV | 3.1 | 7.9 | 3.08 [1.65–5.76] | < 0.001 * | 2.87 [1.53–5.41] | < 0.01 $ * |
Type of treatment | ||||||
HFRT + TMZ | 5.5 | 18.9 | ||||
Stupp | 9.6 | 24.2 | 0.74 [0.46–1.20] | 0.22¤ | ||
HFRT | 3.9 | 8.8 | ||||
HFRT + TMZ or Stupp | 5.9 | 22.9 | 0.6 [0.40–0.92] | < 0.05§ | 0.54 [0.33–0.88] | < 0.05 # $ § |